病例报告:纠正过度左甲状腺素治疗后严重骨质疏松快速逆转并长期随访
本病例报告描述一名38岁女性,在多年过度左甲状腺素治疗后出现双侧股骨应力性骨折和骨质疏松。减少左甲状腺素剂量后,其骨健康迅速恢复并长期维持,无需骨活性药物治疗,随访23年无骨折。
要点
- 过度左甲状腺素治疗可导致严重继发性骨质疏松和应力性骨折。
- 减少左甲状腺素剂量后骨密度和骨钙素水平迅速正常化。
- 随访23年(跨越绝经期)无骨折发生,无需骨活性治疗。
核心结论
- 过度TSH抑制 contributed to 该患者的继发性骨质疏松;减少左甲状腺素剂量后骨密度正常化,随访23年无骨折发生。
- 部分患者在接受过度左甲状腺素替代治疗时可发生严重骨质疏松,对左甲状腺素补充患者进行良好随访是必须的。
研究设计与样本
- 病例报告,描述一名38岁女性的长期随访数据。
主要发现
- 患者表现为双侧股骨应力性骨折和骨质疏松,此前有多年过度左甲状腺素治疗史。
- 减少左甲状腺素剂量后,骨密度和先前升高的血清骨钙素水平迅速正常化。
- 随访23年(跨越绝经期)期间无骨折发生。
关键数值与推荐
- 原文未报告具体骨密度数值或骨钙素数值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This case report describes a 38-year-old woman, who presented with bilateral femoral stress fractures and osteoporosis after years of excessive levothyroxine treatment. Her bone health was restored rapidly and long-lasting with the reduction of levothyroxine dosage. No bone-active treatment was warranted. INTRODUCTION: Hyperthyroidism is a known risk factor for osteoporosis and fractures. Recent studies on patients with serum thyrotropin-suppressive therapy have not, however, indicated adverse effects on bone during long-term follow-up. METHODS: This case report describes long-term follow-up data of a clinically euthyreoid patient, who developed symptomatic osteoporosis due to excessive levothyroxine treatment. RESULTS: After correction of levothyroxine dosage, her bone mineral density (BMD) and previously elevated serum osteocalcin levels normalized rapidly and she remained free from fractures during 23 years of follow-up over menopause. CONCLUSION: Excessive TSH suppression contributed to the secondary osteoporosis in this patient; BMD normalized after dose reduction of levothyroxine and no fractures occurred during 23 years' follow-up. Some patients develop severe osteoporosis if they are over-substituted with levothyroxine, and decent follow-up of patients with levothyroxine supplementation is mandatory.
引用
- Laine CM, Landin-Wilhelmsen K. Case report: fast reversal of severe osteoporosis after correction of excessive levothyroxine treatment and long-term follow-up. Osteoporos Int. 2017. PMID: 28324131. doi:10.1007/s00198-017-3981-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。